COCP

MKT CAP:$15M

Cocrystal Pharma, Inc.

Market Cap

$15M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.38+$0.39 (+39.00%)

Apr 24, 2026

Company Details

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs prima...

CEO

Sam Lee

IPO Date

Feb 22, 2012

Website

www.cocrystalpharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$9M

EPS (Diluted)

-$0.80

Free Cash Flow

-$8M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 31, 2026

$0EPS -$0.78

Q4 2025

Mar 31, 2026

$0EPS -$0.18

Q3 2025

Nov 14, 2025

$0EPS -$0.19

Q2 2025

Aug 14, 2025

$0EPS -$0.20

Q1 2025

May 15, 2025

$0EPS -$0.23

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$3M	-$4M
Q2 22	$0	-$2M	-$24M
Q3 22	$0	-$4M	-$6M
Q4 22	$0	-$3M	-$5M
Q1 23	$0	-$4M	-$5M
Q2 23	$0	-$3M	-$4M
Q3 23	$0	-$4M	-$4M
Q4 23	$0	-$4M	-$5M
Q1 24	$0	-$3M	-$4M
Q2 24	$0	-$4M	-$5M
Q3 24	$0	-$3M	-$5M
Q4 24	$0	-$28.0K	-$3M
Q1 25	$0	-$1M	-$2M
Q2 25	$0	-$21.0K	-$2M
Q3 25	$0	-$13.0K	-$2M
Q4 25	$0	$1M	-$2M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$4M	-$4M
Q2 22	-$4M	-$4M
Q3 22	-$9M	-$9M
Q4 22	-$5M	-$5M
Q1 23	-$3M	-$3M
Q2 23	-$6M	-$6M
Q3 23	-$3M	-$3M
Q4 23	-$3M	-$3M
Q1 24	-$5M	-$5M
Q2 24	-$4M	-$4M
Q3 24	-$5M	-$5M
Q4 24	-$3M	-$3M
Q1 25	-$3M	-$3M
Q2 25	-$2M	-$2M
Q3 25	-$2M	-$2M
Q4 25	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$62.0K
Q4 22	$12.0K
Q1 23	$45.0K
Q2 23	$14.0K
Q3 23	$0
Q4 23	$59.0K
Q1 24	$8.0K
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$12.6K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+53.6%
Q2 22	—	+538.1%
Q3 22	—	+44.0%
Q4 22	—	+21.6%
Q1 23	—	+21.5%
Q2 23	—	-82.2%
Q3 23	—	-22.0%
Q4 23	—	+3.6%
Q1 24	—	-18.6%
Q2 24	—	+25.6%
Q3 24	—	+13.5%
Q4 24	—	-30.8%
Q1 25	—	-43.7%
Q2 25	—	-61.3%
Q3 25	—	-58.6%
Q4 25	—	-23.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$239.0K	—
Q2 22	$241.0K	—
Q3 22	$216.0K	—
Q4 22	$159.0K	—
Q1 23	$291.0K	—
Q2 23	$179.0K	—
Q3 23	$173.0K	—
Q4 23	$158.0K	—
Q1 24	$157.0K	—
Q2 24	$148.0K	—
Q3 24	$253.0K	—
Q4 24	$85.0K	—
Q1 25	$82.0K	—
Q2 25	$84.0K	—
Q3 25	$0	—
Q4 25	$56.0K	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$3M	$1M	$19.0K	—
Q2 22	$2M	$1M	—	—
Q3 22	$4M	$2M	—	—
Q4 22	$3M	$1M	—	—
Q1 23	$4M	$1M	$22.0K	—
Q2 23	$3M	$2M	—	—
Q3 23	$4M	$2M	—	—
Q4 23	$4M	$1M	—	—
Q1 24	$3M	$1M	$55.0K	—
Q2 24	$4M	$1M	—	—
Q3 24	$3M	$2M	—	—
Q4 24	$2M	—	—	$1M
Q1 25	$1M	$942.0K	$39.0K	—
Q2 25	$1M	$986.0K	—	—
Q3 25	$954.0K	—	—	$1M
Q4 25	$2M	$862.0K	—	—

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$55M	$0	$55M
Q2 22	$51M	$0	$51M
Q3 22	$42M	$0	$42M
Q4 22	$37M	$0	$37M
Q1 23	$34M	$0	$34M
Q2 23	$32M	$0	$32M
Q3 23	$30M	$0	$30M
Q4 23	$26M	$0	$26M
Q1 24	$22M	$0	$22M
Q2 24	$18M	$0	$18M
Q3 24	$13M	$0	$13M
Q4 24	$10M	$0	$10M
Q1 25	$7M	$0	$7M
Q2 25	$5M	$0	$5M
Q3 25	$8M	$0	$8M
Q4 25	$7M	$0	$7M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	8M	+11.9%	+36.8%
Q2 22	8M	0.0%	+11.9%
Q3 22	8M	+0.3%	0.0%
Q4 22	8M	+0.0%	+12.2%
Q1 23	8M	0.0%	+0.3%
Q2 23	10M	+23.6%	+23.9%
Q3 23	10M	+0.9%	+24.7%
Q4 23	10M	+0.2%	+24.9%
Q1 24	10M	0.0%	+24.9%
Q2 24	10M	0.0%	+1.1%
Q3 24	10M	0.0%	+0.2%
Q4 24	10M	0.0%	0.0%
Q1 25	10M	0.0%	0.0%
Q2 25	10M	0.0%	0.0%
Q3 25	11M	+8.0%	+8.0%
Q4 25	11M	+2.7%	+11.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	13
Q2 22	$0	13
Q3 22	$0	13
Q4 22	$0	12
Q1 23	$0	12
Q2 23	$0	12
Q3 23	$0	12
Q4 23	$0	12
Q1 24	$0	12
Q2 24	$0	12
Q3 24	$0	12
Q4 24	$0	11
Q1 25	$0	11
Q2 25	$0	11
Q3 25	$0	11
Q4 25	$0	10

Revenue / Employee